Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two progestins, desogestrel and etonogestrel, both in their 11-methylene (E-E) forms. Desogestrel is a third-generation synthetic progestin used primarily in oral contraceptives, where it acts as a progesterone receptor agonist to inhibit ovulation and alter cervical mucus and endometrial lining to prevent pregnancy[6][8]. Etonogestrel is the biologically active metabolite of desogestrel and is also used as a contraceptive agent, most notably in subdermal implants or vaginal rings[5][7]. Both drugs act by suppressing the hypothalamic-pituitary-gonadal axis, thereby inhibiting gonadotropin secretion (luteinizing hormone and follicle-stimulating hormone), which prevents ovulation. They also increase cervical mucus viscosity to impede sperm penetration and induce endometrial changes that reduce the likelihood of implantation[2][3][7]. This specific combination (desogestrel + etonogestrel) does not correspond to any approved pharmaceutical product; typically, each drug is combined with an estrogen such as ethinyl estradiol for contraceptive use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on e-e-desogestrel + e-e-etonogestrel.